Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031031 | 1.00 | BACE1 (0.45) | BACE1SIGMAR1EGFRCCR5 | |
| Trifluoroacetic Acid SCHEMBL3479659 | 0.94 | BACE1 (0.41) | BACE1SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL3479366 | 0.94 | BACE1 (0.41) | BACE1SIGMAR1 | |
| SCHEMBL3479475 | 0.86 | BACE1 (0.52) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL3479447 | 0.84 | BACE1 (0.48) | BACE1 | |
| SCHEMBL3479445 | 0.83 | BACE1 (0.58) | BACE1 | |
| SCHEMBL3479443 | 0.83 | BACE1 (0.58) | BACE1 | |
| SCHEMBL3479511 | 0.83 | BACE1 (0.58) | BACE1 | |
| SCHEMBL3479461 | 0.82 | BACE1 (0.40) | BACE1SIGMAR1 | |
| SCHEMBL3479460 | 0.82 | BACE1 (0.40) | BACE1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | claimed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | BACE1 1/4885SIGMAR1 4304/4885EGFR 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.